VILTEPSO
Drug
NS Pharma, Inc.
Total Payments
$2.1M
Transactions
1,700
Doctors
589
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $121,100 | 396 | 215 |
| 2023 | $253,804 | 622 | 244 |
| 2022 | $993,929 | 370 | 181 |
| 2021 | $725,026 | 312 | 144 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.7M | 285 | 82.4% |
| Consulting Fee | $154,710 | 48 | 7.4% |
| Honoraria | $119,487 | 124 | 5.7% |
| Food and Beverage | $43,123 | 1,172 | 2.1% |
| Travel and Lodging | $31,892 | 61 | 1.5% |
| Grant | $19,000 | 10 | 0.9% |
Payments by Type
Research
$1.7M
285 transactions
General
$368,212
1,415 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| NS-065/NCNP-01-202 - A Phase II, Open-Label, Extension Study to Assess the Safety and Efficacy of NS-065/NCNP-01 in Boys with Duchenne Muscular Dystrophy (DMD) | NS Pharma, Inc. | $903,953 | 0 |
| A Phase 2 Open-label Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys with Duchenne Muscular Dystrophy (DMD) Compared to Natural History Controls | NS Pharma, Inc. | $344,980 | 0 |
| Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502) | NS Pharma, Inc. | $185,869 | 0 |
| A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With Duchenne Muscular Dystrophy (DMD) | NS Pharma, Inc. | $121,204 | 0 |
| A Phase 2 Open-label Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys With Duchenne Muscular Dystrophy (DMD) Compared to Natural History Controls | NS Pharma, Inc. | $103,048 | 0 |
| Phase 4, open-label, single-arm clinical trial assessing the long-term safety and efficacy of Viltepso (viltolarsen) in boys with Duchenne muscular dystrophy (DMD) who completed a prior trial | NS Pharma, Inc. | $32,464 | 0 |
| A Phase 3, Multi-center, Open-label Extension Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With Duchenne Muscular Dystrophy (DMD) | NS Pharma, Inc. | $19,064 | 0 |
| A Phase II, Open-Label, Extension Study to Assess the Safety and Efficacy of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD) | NS Pharma, Inc. | $10,064 | 0 |
| A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys with Duchenne Muscular Dystrophy (DMD) | NS Pharma, Inc. | $5,000 | 0 |
Top Doctors Receiving Payments for VILTEPSO — Page 20
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , APRN | Nurse Practitioner | Bedford, TX | $19.08 | 1 |
| , MD | Neurology | Bedford, TX | $19.08 | 1 |
| , M.D | Neurology | Bedford, TX | $19.08 | 1 |
| , M.D | Neurology | Bedford, TX | $19.08 | 1 |
| , MD | Student in an Organized Health Care Education/Training Program | Dallas, TX | $19.04 | 1 |
| , MD | Neurology | Dallas, TX | $19.04 | 1 |
| , M.D | Neurology | Dallas, TX | $19.04 | 1 |
| , FNP | Family Medicine | Dallas, TX | $19.04 | 1 |
| , FNP-C | Family | Dallas, TX | $19.04 | 1 |
| , MD | Neurology | Dallas, TX | $19.04 | 1 |
| , MD | Pediatrics | Carmel, IN | $18.72 | 1 |
| , MD | Pediatrics | Carmel, IN | $18.72 | 1 |
| , MD | Pediatrics | Indianapolis, IN | $18.72 | 1 |
| , M.D | Pediatric Pulmonology | San Diego, CA | $18.67 | 1 |
| , MD | Neurology | San Diego, CA | $18.67 | 1 |
| , PA-C | Medical | Omaha, NE | $18.65 | 1 |
| , PA | Physician Assistant | Omaha, NE | $18.65 | 1 |
| Kevin Griffith | Public Health & General Preventive Medicine | Durango, CO | $18.63 | 1 |
| , ARNP | Family | Miami, FL | $18.58 | 1 |
| , M.D | Clinical Neurophysiology | Miami, FL | $18.58 | 1 |
| , MD | Neurology with Special Qualifications in Child Neurology | Chicago, IL | $18.57 | 1 |
| , FNP | Family | Rogersville, TN | $18.32 | 1 |
| , MD | Student in an Organized Health Care Education/Training Program | Jackson, MS | $18.23 | 1 |
| Nawal Shaikh | Neurology | Jackson, MS | $18.23 | 1 |
| , MD | Pediatrics | Dallas, TX | $18.21 | 1 |
Ad
Manufacturing Companies
- NS Pharma, Inc. $2.1M
- Nippon Shinyaku Co.,Ltd $1,765
Product Information
- Type Drug
- Total Payments $2.1M
- Total Doctors 589
- Transactions 1,700
About VILTEPSO
VILTEPSO is a drug associated with $2.1M in payments to 589 healthcare providers, recorded across 1,700 transactions in the CMS Open Payments database. The primary manufacturer is NS Pharma, Inc..
Payment data is available from 2021 to 2024. In 2024, $121,100 was paid across 396 transactions to 215 doctors.
The most common payment nature for VILTEPSO is "Unspecified" ($1.7M, 82.4% of total).
VILTEPSO is associated with 9 research studies, including "NS-065/NCNP-01-202 - A Phase II, Open-Label, Extension Study to Assess the Safety and Efficacy of NS-065/NCNP-01 in Boys with Duchenne Muscular Dystrophy (DMD)" ($903,953).